文献速递淋巴瘤

靶向CD70的抗体药物偶联物在患者来源的皮肤T细胞淋巴瘤异种移植模型中的研究

Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
PubMed 文献 · Blood Adv · 2022-01-01

研究检测了49例T细胞淋巴瘤诊断标本中CD70的表达,并在皮肤T细胞淋巴瘤(CTCL)细胞系、原发肿瘤细胞及患者来源异种移植(PDX)模型中评估CD70抗体药物偶联物SGN-CD70A的活性。结果显示CD70在T细胞淋巴瘤尤其CTCL中高表达,SGN-CD70A可抑制细胞生长并诱导凋亡,在PDX中呈剂量依赖性延长生存,300 μg/kg多次给药优于单次给药(中位生存111天 vs 39天,P = .017),且多次给药可使已建立的肿瘤完全清除。

要点

  • CD70在T细胞淋巴瘤尤其CTCL中高表达,为潜在治疗靶点。
  • SGN-CD70A在CD70阳性CTCL细胞系和原发肿瘤细胞中抑制生长并诱导凋亡。
  • PDX模型中300 μg/kg多次给药较单次给药延长生存(中位111天 vs 39天,P = .017)并使肿瘤完全清除。

核心结论

  • SGN-CD70A在CTCL患者来源异种移植模型中显示出显著抗肿瘤活性,为临床研究提供了有力支持。

研究设计与样本

  • 研究为临床前研究,采用49例T细胞淋巴瘤诊断标本进行免疫组化检测CD70表达,并在CTCL细胞系、原发肿瘤细胞及既往建立的CTCL患者来源异种移植(PDX)模型中进行。
  • 在PDX动物中先进行剂量探索试验,随后进行类2期试验以评估SGN-CD70A的最佳剂量和疗效。

主要发现

  • CD70在T细胞淋巴瘤中高表达,尤其在CTCL中。
  • SGN-CD70A在表达CD70的CTCL细胞系和原发肿瘤细胞中抑制细胞生长并诱导凋亡。
  • SGN-CD70A在100 μg/kg和300 μg/kg剂量下呈剂量依赖性延长PDX生存。
  • 300 μg/kg剂量3次给药较单次给药延长生存更优(中位生存111天 vs 39天;P = .017)。
  • 多次给药SGN-CD70A通过cfDNA检测使PDX中已建立的肿瘤完全清除。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD70 is a member of the tumor necrosis factor receptor superfamily. Emerging data indicate that CD70 may be a suitable target for various malignancies. We investigated the expression of CD70 in cutaneous and systemic T-cell lymphomas and conducted preclinical studies of SGN-CD70A, a CD70-directed antibody-drug conjugate (ADC), using patient-derived xenograft cutaneous T-cell lymphoma (CTCL PDX) models. CD70 expression was examined by immunohistochemical (IHC) stains in 49 diagnostic specimens of T-cell lymphomas. The activities of SGN-CD70A in growth inhibition and apoptosis induction were examined in CTCL cell lines and primary CTCL tumor cells. Using previously established CTCL PDXs, we conducted a dose-finding trial followed by a phase 2-like trial to evaluate the optimal dosing and the efficacy of SGN-CD70A in tumor-bearing PDX animals. The therapeutic efficacy of SGN-CD70A was measured by tumor-associated cell-free DNA (cfDNA) and survival of treated PDXs. We found that CD70 is highly expressed in T-cell lymphomas, especially in CTCL. SGN-CD70A inhibited cell growth and induced apoptosis in CD70-expressing CTCL cell lines and primary tumors cells. Additionally, SGN-CD70A at 100 μg/kg and 300 μg/kg prolonged the survival of PDXs in a dose-dependent manner. Finally, treatment with 3 doses of SGN-CD70A at 300 μg/kg was superior to a single-dose treatment in survival prolongation (median survival: 111 days vs 39 days; P = .017). Most importantly, multiple dosing of SGN-CD70A induced complete eradication of established tumors in PDXs measured by cfDNA. Our results demonstrated marked antitumor activity of SGN-CD70A in CTCL PDXs, providing compelling support for its clinical investigation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wu CH, Wang L, Yang CY, et al. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Adv. 2022. PMID: 34872108. doi:10.1182/bloodadvances.2021005714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。